- Here's Why Goldman Sachs Downgraded Cisco
- This Is How One Large Options Trader Expects Kohl's To Move
- ESSA Pharma Announces First Patient Dosed In Phase 1/2 Clinical Trial Of EPI-7386 In Combination With Enzalutamide In Patients With Metastatic Castration-Resistant Prostate Cancer
- Gamida Cell Says Planning To Initiate Rolling BLA Submission For Omidubicel; Full BLA Submission On Track For 1H 2022
- Tractor Supply To Retail Greenworks Pro 60V Outdoor Equipment
- Ginkgo Bioworks Announces Acquisition Of Massachusetts COVID-19 Testing Provider Project Beacon COVID-19 LLC; Terms Not Disclosed
- Jim Cramer Shares His Thoughts On T-Mobile, Veeva Systems And More
- Regeneron Announces FDA Accepts For Review Libtayo In Combination With Chemotherapy For First-Line Treatment Of Advanced NSCLC
- Fastenal: Q4 Earnings Insights
- CNBC's Final Trades: Wynn Resorts, Goldman Sachs, Berkshire Hathaway And This Pharma Major
About Benzinga
Benzinga is a dynamic and innovative financial media outlet that empowers investors with high-quality, unique content that is coveted by Wall Street’s top traders. Benzinga provides timely, actionable ideas that help users navigate even the most uncertain and volatile markets – in real-time with an unmatched caliber.
From breakouts to unusual volume, analyst ratings, futures, and options, Benzinga is the leading full-service, a one-stop-shop for investors of all stripes and styles.